Literature DB >> 11553938

Neuroprogressive disease of post-infectious origin: a review of a resurging subacute sclerosing panencephalitis (SSPE).

P R Dyken1.   

Abstract

Subacute sclerosing panencephalitis (SSPE) is a progressive, essentially untreatable, disease of the nervous system. When first described in the 20th Century, it was characterized more for its neuropathological features than for its pathophysiology or cause. It was not until the 1960s that a clear relationship to the measles virus was established. It is now thought that this uncommon infectious encephalopathy is caused by a "slow," altered or persistent form of the wild measles virus which has harbored in the nervous system for years. Then a "breakout" occurs and the more lytic and virulent organisms produce the progressive and spreading inflammatory and destructive lesions which are confined to the nervous system. Epidemiological study of the disease confirms its relationship to measles. In the years since the development of national measles immunization programs, there has been a dramatic decline in the incidence of measles exanthem and until recently a corresponding decline in the incidence of SSPE. In recent years there has been a mild to moderate increase in cases of SSPE as reported to the USA/International SSPE Registry. As yet, there has not been a totally effective treatment. The purpose of this paper is to give an overall review on SSPE and its relationship to measles. This review will include a prospectus of its history, considerations as to its etiology, correlation of clinicopathological features, and thoughts on the past and present epidemiology and treatment. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2001        PMID: 11553938     DOI: 10.1002/mrdd.1030

Source DB:  PubMed          Journal:  Ment Retard Dev Disabil Res Rev        ISSN: 1080-4013


  8 in total

1.  Challenges in diagnosing SSPE.

Authors:  Ozdem Erturk; Beyhan Karslıgil; Ozlem Cokar; Zuhal Yapici; Veysi Demirbilek; Candan Gurses; Cengiz Yalcinkaya; Aysen Gokyigit; Guher Saruhan Direskeneli; Sibel Yentur; Emel Onal; Gulden Yilmaz; Aysin Dervent
Journal:  Childs Nerv Syst       Date:  2011-10-15       Impact factor: 1.475

2.  Interleukin-12 (-1188) A/C and interferon-γ (+874) A/T gene polymorphisms in subacute sclerosing panencephalitis patients.

Authors:  Nihal Olgac Dundar; Pinar Gencpinar; Nilgun Sallakci; Ozgur Duman; Senay Haspolat; Banu Anlar; Olcay Yegin
Journal:  J Neurovirol       Date:  2016-04-21       Impact factor: 2.643

3.  Detection of interleukin 10 in cerebrospinal fluid of patients with subacute sclerosing panencephalitis.

Authors:  A S Mistchenko; M C Fornari; M Viegas; P R Barrero; R A Diez
Journal:  J Neurovirol       Date:  2005-02       Impact factor: 2.643

4.  Interleukin (IL)-12, IL-2, interferon-gamma gene polymorphisms in subacute sclerosing panencephalitis patients.

Authors:  Vuslat Yilmaz; Veysi Demirbilek; Candan Gürses; Sibel P Yentür; Serap Uysal; Zuhal Yapici; Gülden Yilmaz; Aaron Muncey; Ozlem Cokar; Emel Onal; Aysen Gökyiğit; Güher Saruhan-Direskeneli
Journal:  J Neurovirol       Date:  2007-10       Impact factor: 2.643

5.  Indication of peripheral nerve hyperexcitability in adult-onset subacute sclerosing panencephalitis (SSPE).

Authors:  Annabel Schreurs; Erik V Stålberg; Anna Rostedt Punga
Journal:  Neurol Sci       Date:  2008-05-16       Impact factor: 3.307

Review 6.  Options in the Treatment of Subacute Sclerosing Panencephalitis: Implications for Low Resource Areas.

Authors:  Pauline Samia; Katherine Oyieke; Dorcas Tunje; Anaita Udwadia-Hegde; Kristen Feemster; Ibrahim Oncel; Banu Anlar
Journal:  Curr Treat Options Neurol       Date:  2022-03-19       Impact factor: 3.972

7.  Role of carbamazepine in the symptomatic treatment of subacute sclerosing panencephalitis: a case report and review of the literature.

Authors:  Sandhya Ravikumar; John Ross Crawford
Journal:  Case Rep Neurol Med       Date:  2013-03-07

8.  Retinitis as the presenting feature of subacute sclerosing panencephalitis in an Indian male: A case report.

Authors:  Amravi Shah; Rajesh Babu; Jyotirmoy Biswas
Journal:  Indian J Ophthalmol       Date:  2018-10       Impact factor: 1.848

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.